JP2019516775A - プロバイオティクス及び消化酵素の組成物並びにその調製方法及び使用 - Google Patents

プロバイオティクス及び消化酵素の組成物並びにその調製方法及び使用 Download PDF

Info

Publication number
JP2019516775A
JP2019516775A JP2018562173A JP2018562173A JP2019516775A JP 2019516775 A JP2019516775 A JP 2019516775A JP 2018562173 A JP2018562173 A JP 2018562173A JP 2018562173 A JP2018562173 A JP 2018562173A JP 2019516775 A JP2019516775 A JP 2019516775A
Authority
JP
Japan
Prior art keywords
lactobacillus
billion cfu
probiotics
bifidobacterium
billion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2018562173A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516775A5 (https=
Inventor
キム シェーファー、
キム シェーファー、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2019516775A publication Critical patent/JP2019516775A/ja
Publication of JP2019516775A5 publication Critical patent/JP2019516775A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01001—Alpha-amylase (3.2.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01003—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01004—Cellulase (3.2.1.4), i.e. endo-1,4-beta-glucanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01008—Endo-1,4-beta-xylanase (3.2.1.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01026—Beta-fructofuranosidase (3.2.1.26), i.e. invertase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01108—Lactase (3.2.1.108)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22002—Papain (3.4.22.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22032—Stem bromelain (3.4.22.32)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2018562173A 2016-05-24 2016-05-24 プロバイオティクス及び消化酵素の組成物並びにその調製方法及び使用 Ceased JP2019516775A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2016/033976 WO2017204788A1 (en) 2016-05-24 2016-05-24 Composition of probiotics and digestive enzymes and method of preparing and using the same

Publications (2)

Publication Number Publication Date
JP2019516775A true JP2019516775A (ja) 2019-06-20
JP2019516775A5 JP2019516775A5 (https=) 2019-07-25

Family

ID=60411761

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018562173A Ceased JP2019516775A (ja) 2016-05-24 2016-05-24 プロバイオティクス及び消化酵素の組成物並びにその調製方法及び使用

Country Status (12)

Country Link
US (1) US20200323929A1 (https=)
EP (1) EP3463404A4 (https=)
JP (1) JP2019516775A (https=)
KR (1) KR102380198B1 (https=)
CN (1) CN109451727A (https=)
AU (1) AU2016408376B2 (https=)
BR (1) BR112018074355A2 (https=)
CA (1) CA3025512A1 (https=)
IL (1) IL263238A (https=)
MX (1) MX2018014500A (https=)
RU (1) RU2018144897A (https=)
WO (1) WO2017204788A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023093682A (ja) * 2019-08-30 2023-07-04 エイチイエム ファーマ インコーポレイテッド Ｐｍａｓ方法を利用したパーソナライズ腸内環境改善物質スクリーニング方法
JP2023159522A (ja) * 2022-04-20 2023-11-01 国立大学法人 和歌山大学 短鎖脂肪酸産生促進用組成物
US12282026B2 (en) 2019-08-30 2025-04-22 Hem Pharma Inc. Method for screening personalized intestinal environment-improving material and composition therefor

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3055915A1 (en) * 2017-03-10 2018-09-13 Biohm Health Llc Compositions and methods for disrupting biofilms of pathogenic bacteria or fungi
WO2019169179A1 (en) * 2018-02-28 2019-09-06 Shafer Kim Augmenting efficacy of cancer therapies using probiotic based compositions
US20210030818A1 (en) * 2018-03-09 2021-02-04 Biohm Health Llc Compositions for use in balancing microbiome
CN109528776A (zh) * 2018-06-08 2019-03-29 广东益可维健康科技有限公司 一种预防治疗口腔疾病的复合益生菌含片及其制备方法
CN109566935A (zh) * 2018-12-06 2019-04-05 张秋环 综合益生菌复合粉固体饮料的制备方法
TWI740101B (zh) * 2019-02-12 2021-09-21 大江生醫股份有限公司 降膽固醇之益生菌株的用途
KR102119133B1 (ko) 2019-05-02 2020-06-26 선정완 유산균 분말 및 노니 분말을 포함하는 프로바이오틱스 조성물
KR102335928B1 (ko) * 2019-10-02 2021-12-08 한국생명공학연구원 비만의 예방, 치료 또는 개선용 조성물
CN111213885A (zh) * 2020-01-20 2020-06-02 齐海心 一种具有调节血脂功效的益生菌组合物及其制备方法与应用
TW202203950A (zh) * 2020-03-30 2022-02-01 香港商香港微生物菌群創新中心有限公司 微生物在調節體重和膽固醇水準中的用途
CN111558033A (zh) * 2020-05-14 2020-08-21 广州中昱医学生物科技有限公司 一种口腔清洁组合物及其应用
CN112021575A (zh) * 2020-09-17 2020-12-04 泉州亚林新材料科技有限公司 一种益生菌组合物及其制备方法
KR20230156825A (ko) * 2021-01-19 2023-11-14 에이티알 쓰라이브 엘엘씨 성인 영양을 위한 우유와 효소의 조성물
CN113244408A (zh) * 2021-06-02 2021-08-13 河北源民生物科技有限公司 一种适用于肠胃的益生菌组合物
CN115025132B (zh) * 2022-06-09 2024-01-30 康永波 一种合生元组合物及其制备方法和应用
CN116042486B (zh) * 2023-02-22 2024-11-08 高邮市人民医院 一种用于治疗动脉粥样硬化的复合菌制剂
WO2025076281A1 (en) * 2023-10-06 2025-04-10 Biohm Health Inc. Microbiome modulating formula for menopausal-aged women

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432097B2 (en) * 1997-08-13 2008-10-07 Verenium Corporation Phytases, nucleic acids encoding them and methods of making and using them
US6436451B1 (en) * 1999-03-26 2002-08-20 Eggland's Best, Inc. Method of reducing cholesterol in chicken eggs
US6368617B1 (en) * 2001-05-15 2002-04-09 Reliv' International, Inc. Dietary supplement
US20040071685A1 (en) * 2002-10-09 2004-04-15 Devin Houston Compositions and methods for increasing the bioavailability of plant polyphenols
GB2465814B (en) * 2008-06-19 2011-10-26 Tarig Sayed Mustafa Arbab Method,composition and device for the treatment of enzymes and saccharides disorders
US8257694B2 (en) * 2009-05-14 2012-09-04 Product Partners, Llc Nutritional compositions for reducing oxidative damage
BR112012024674B1 (pt) * 2010-04-26 2019-07-02 Novozymes A/S Grânulo, e, composição de detergente granular
US9301983B2 (en) * 2014-03-07 2016-04-05 Genmont Biotech Inc. Composition and method of Lactobacillus reuteri GMNL-89 in treating type 2 diabetes
WO2015172191A1 (en) * 2014-05-12 2015-11-19 Medlab Ip Pty Ltd Probiotic compositions and uses thereof for treatment of obesity-related disorders
AU2015100952A4 (en) * 2014-07-17 2015-08-20 Pharm-A-Care Laboratories Pty Ltd Probiotic- and enzyme-containing compositions and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HALL, SEAN;VITETTA, LUIS;COULSON, SAMANTHA: "PROBIOTIC-AND ENZYME-CONTAINING COMPOSITIONS AND USES THEREOF", オーストラリア特許公報, vol. AU 2015100952 A4 オーストラリア特許, JPN5019004630, 20 August 2015 (2015-08-20), AU, ISSN: 0004265030 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023093682A (ja) * 2019-08-30 2023-07-04 エイチイエム ファーマ インコーポレイテッド Ｐｍａｓ方法を利用したパーソナライズ腸内環境改善物質スクリーニング方法
JP7587872B2 (ja) 2019-08-30 2024-11-21 エイチイエム ファーマ インコーポレイテッド Ｐｍａｓ方法を利用したパーソナライズ腸内環境改善物質スクリーニング方法
US12282026B2 (en) 2019-08-30 2025-04-22 Hem Pharma Inc. Method for screening personalized intestinal environment-improving material and composition therefor
JP2023159522A (ja) * 2022-04-20 2023-11-01 国立大学法人 和歌山大学 短鎖脂肪酸産生促進用組成物

Also Published As

Publication number Publication date
CN109451727A (zh) 2019-03-08
BR112018074355A2 (pt) 2019-03-06
IL263238A (en) 2018-12-31
RU2018144897A3 (https=) 2020-06-25
AU2016408376B2 (en) 2020-10-22
KR102380198B1 (ko) 2022-03-29
AU2016408376A1 (en) 2019-01-17
WO2017204788A1 (en) 2017-11-30
CA3025512A1 (en) 2017-11-30
EP3463404A4 (en) 2020-03-11
KR20190015718A (ko) 2019-02-14
US20200323929A1 (en) 2020-10-15
RU2018144897A (ru) 2020-06-25
EP3463404A1 (en) 2019-04-10
MX2018014500A (es) 2019-04-15

Similar Documents

Publication Publication Date Title
AU2016408376B2 (en) Composition of probiotics and digestive enzymes and method of preparing and using the same
JP6882931B2 (ja) プレバイオティック製剤および使用方法
EP1513541B1 (en) Method for preventing or alleviating symptoms of malabsorption from the gastrointestinal tract
EP3986163A2 (en) Microbial compositions and methods for producing upgraded probiotic assemblages
JP2013518842A (ja) 乳糖不耐症またはラクターゼ欠乏症から起こる症状の治療に使用するための組成物
JP2025519402A (ja) ビタミンＣ及びビフィドバクテリウム・アニマリス亜種ラクティス（Ｂｉｆｉｄｏｂａｃｔｅｒｉｕｍ ａｎｉｍａｌｉｓ ｓｓｐ．ｌａｃｔｉｓ）を含む組み合わせ
CN106974940A (zh) 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用
Cuoco Effect of exogenous β-galactosidase in patients with lactose malabsorption and intolerance: a crossover double-blind placebo-controlled study
Rao et al. Probiotics and Diet for Chronic Diseases Prevention
HK1166236B (en) Prebiotic formulations and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200817

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201215

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20210511